Viagra Super Active+ (Sildenafil)

Based on case reports and studies conducted with sildenafil todate, an initial dose of 0. 25 to 0. 5 mg / kg / dose of 4 / 4 8 / 8 hours isrecommended for pediatrics patients with pulmonary hypertension. The adjustment should be done according to the answer. 2 mg/Kg/dose dose above the 4 / 4 hours can not provideadicionaids benefits, although it was not given the maximum dose 40.

Based on current understanding of the molecular basis of action of sildenafil, morestudies are needed to better understand the action of sildenafil in PPH of the newborn. Theroute of administration may be a key factor in determining its use in infants critic (6 gastrointestinal absorption may be impractical in these infants). These infants present a risk of intestinal ischemia secondary to hypoxia. The Aerosol therapy may be a difficulty in infants with severe meconium aspiration in theonly by the need for continued treatment given the short action of sildenafiladministered by this route, but also because of limited distribution in the presence ofmeconium and inflammatory exudate. The formulation of intravenous (IV), however it seems moreappropriate for these patients 6. Shekerdemian and cl 6, Denmark, studied the effects of the use of sildenafil in EVpulmonary hemodynamics and oxygenation, and compared these effects with i NO in aanimal model (pigs) l newborn pulmonary hypertension secondary to aspirationmeconium. The authors instilled via tracheal meconium in 18 piglets, six subsequently IV received sildenafil for 2 hs, six received i NO for 2 pm and 6 animals received noadditional intervention. The meconium aspiration increased pulmonary vascular resistancein 70% and the oxygenation index at 100%. The piglets receiving i NO fellpulmonary vascular resistance by 40% after 2 hours of treatment, the pigletssildenafil were reversed by the high resists complete vascular AGENCY within 1 h ofinfusion. The control animals remained high vascular resistance throughout the study. There was no effect on systemic hemodynamics. Sildenafil increased the debtheart in 30%, but did not impair oxygenation. Assi m, the authors concluded that the Sildenafil is a selective pulmonary vasodilator and highly effective (as effective as INO) in this model of neonatal pulmonary hypertension. The pharmacokinetics of sildenafil EV is not determined. The dose used in the model Shekerdemiane of CL 6 was extrapolated from oral doses (12 mg / kg) in patientsand a small pediatrics study using 1 mg / kg IV in children undergoingcardiac catheterization. The maximum pulmonary vasodilatory effect occur in the latefirst hour. The continued infusion did not reduce pulmonary vascular resistance more, but caused no adverse effects. A dose of 2 mg / kg IV used in this studyappeared to be well tolerated, but the authors emphasize the importance of studiespharmacokinetics in determining an optimal dose. Despite evidence of synergism between sildenafil and i NO in the potentiationpulmonary vasodilation in older children with primary pulmonary hypertension andpulmonary hypertension following cardiac surgery, f act that was not observed in the study 41 Australian Shekerdemian of 2004 and cl. The authors studied the interaction betweenpulmonary hypertension and acute lung injury secondary to meconium aspiration in 12 newborn piglets: 6 animals (controls) received no intervention after instillationmeconium and 6 animals received i NO (20 ppm) with intravenous sildenafil (2 mg/kg). This is a model of acute pulmonary hypertension with acute lung injury without shuntintracardiac. The i NO reduced the mean pulmonary artery pressure and vascular resistancewithout influencing pulmonary oxygenation. The addition of sildenafil further reduced Mean pulmonary artery pressure and increased cardiac output and reducedpulmonary vascular resistance. However, the authors rel tied that sildenafil decreasedsystemic arterial pressure and systemic vascular resistance, producing a deeparterial hypoxemia, reducing Pa O 2 6923 mm Hg for 4915 mm Hg, despite theincreased Fi O 2 and mean airway pressure. Assi m, the oxygenation index increasedsignificantly (p = 0. 01).The synergism between sildenafil and i NO in the treatment of pulmonary hypertension inmodel and CL 9 Thusu in children with pulmonary hypertension in studies and Atz 12 42 Wessel and adults oc orreu without the concurrence of lung injury. The interactionbetween sildenafil and i NO in the presence of lung injury has been rarely reported in 43 literature. The classic study by Thebaud and showed improvement in pulmonary vasodilation in Infants with congenital diaphragmatic hernia by PPH not responsive to i NO associating i NOto dipyridamole, although the improvement was transient and both patients died (These authors subsequently reported that no response to i NO in diaphragmatic herniacongenita is due to an altered activity of guanylylciclase 37). Recently, Keller andcl 45 reported a case of chronic pulmonary hypertension in a child 7 weeksof age with congenital diaphragmatic hernia, the stabilization of the child and the withdrawal of i NOwith u so sildenafil. Bigatello and cl 46 reported diminished intracardiac shunt in a patient DEadult (52 years) with severe interstitial pulmonary fibrosis and pulmonary hypertensioni NO was using. Pa O 2 increased by 76% with i NO, 40% with silden Afilisolated and 112% with sildenafil associated with i NO. However, Adrie and cl 47 evidenciaramworsening of the response to i NO with the use of zaprinast in an animal model of lung injuryacute, suggesting that the phosphodiesterase inhibitor induces vasodilation in diffuse regionspoorly ventilated and thereby abolishing the beneficial effects observed with the use of i NOisolated. The mechanism by which the use of a phosphodiesterase inhibitor associated with i NOworsening oxygenation in cases of acute pulmonary hypertension and lung injury without shuntintracardiac, probably due to redirection of blood flow to ventilated regions andselectively dilated by i NO in areas not ventilated. The consequence of this is theincreased intrapulmonary shunt, with exacerbation of hi poxemia pressure. 41 Shekerdemian and cl attributed to this mechanism the worst oxygenation observed inmodel of pulmonary hypertension following neonatal meconium aspiration treated withsildenafil and i NO. These facts did not occur in the same model of these authors, 1998, when sildenafil was used alone, and there were no significant changeshemodynamics in 6. The decrease in systemic blood pressure in the study of Shekerdemian and CL 41, also reported in studies of Weimann and cl 16 (down 12% back after cumulative dose 18 Maximum sildenafil) and Kleinsasser and cl (after highdose sildenafil) was assignedpart to the relative hypoxia with sildenafil in this model. Although it is expected that sildenafil was a selective pulmonary vasodilator, small randomized study of Stocker and 48 cl with intravenous sildenafil and nitrous Nitric cardca in children after surgery, showed that sildenafil reduced bothpulmonary and systemic resistance, worsening oxygenation tion and alveolararterial O 249 Juliana and Abbad reported immediate improvement in oxygenation with subsequentcomplete recovery with the use of sildenafil (1. 5 mg / kg) via nasogastric tube ina newborn with severe PPH. Although the term infants have been ventilated with highpressures and have received high doses of cardiovascular pressors, low Pa O 2 persistedwith an alveolararterial O 2 651 mm Hg. The authors discuss the usepotential of phosphodiesterase5 inhibitors such as sildenafil, in situations where nohas the use of nitric oxide and extracorporeal membrane oxygenation.